Compugen(US:CGEN)2025-11-10 12:00Financial Performance - Compugen reported approximately $1.9 million in revenues for Q3 2025, a decrease of 88.9% compared to $17.1 million in Q3 2024[7] - Compugen reported a net loss of approximately $6.98 million in Q3 2025, compared to a net profit of approximately $1.28 million in Q3 2024[9] - Total assets as of September 30, 2025, were approximately $97.8 million, down from $115 million at the end of 2024[17] Expenses - R&D expenses for Q3 2025 were approximately $5.8 million, down from $6.3 million in Q3 2024, reflecting a 7.9% reduction[8] - General and administrative expenses were approximately $2.2 million in Q3 2025, compared to $2.6 million in Q3 2024, a decrease of 15.4%[9] Cash Position - As of September 30, 2025, Compugen had approximately $86.1 million in cash and cash equivalents, expected to fund operations into Q3 2027[5] - Approximately 0.8 million shares were sold through the ATM facility in October 2025, contributing net proceeds of approximately $1.6 million[6] Strategic Initiatives - The company is advancing its differentiated IO pipeline and leveraging its AI/ML powered computational discovery platform Unigen™[3] - Interim analysis for the ongoing MAIA-ovarian platform trial evaluating COM701 is now estimated for Q1 2027[4] - Compugen's partnership with AstraZeneca and Gilead offers over $1 billion in potential milestones and royalties[3]